Mode
Text Size
Log in / Sign up
N/A N=345 Randomized Single-blind Treatment

Safety and Efficacy Study Comparing ProDisc-C to ACDF Surgery to Treat SCDD

Symptomatic Cervical Disc Disease

Enrolled (actual)
345
Serious AEs
45.2%
Results posted
Mar 2017
Primary outcome: Primary: Overall Success — 62.8; 53.2; 62.7 % of Subjects

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Total Disc Replacement (Device); ACDF (Device)
Age
Adult · 18+ yrs
Sex
All
Sponsor
Synthes USA HQ, Inc.
Primary completion
Mar 2015

Outcome Measures

OutcomeResultp-value
PRIMARY
Overall Success
62.8; 53.2; 62.7
SECONDARY
Neurologic Success
87.0; 89.1; 93.5
SECONDARY
NDI
84.6; 84.4; 81.7; 9.0; 9.4; 9.7
SECONDARY
SF-36 Physical Composite Score (PCS)
78.2; 74.2; 68.9; 7.7; 16.1; 11.1
SECONDARY
SF-36 Mental Composite Score (MCS)
52.6; 50.0; 54.4; 19.2; 22.6; 21.1
SECONDARY
VAS Satisfaction
86.16; 82.09; 86.51
SECONDARY
VAS Neck Pain Intensity
76.9; 72.6; 78.5; 10.3; 14.5; 17.2
SECONDARY
VAS Neck Pain Frequency
78.2; 74.2; 73.1; 10.3; 11.3; 12.9
SECONDARY
VAS Arm Pain Intensity
66.7; 74.2; 68.8; 16.7; 9.7; 15.1
SECONDARY
VAS Arm Pain Frequency
61.5; 75.4; 66.7; 21.8; 8.2; 15.1
SECONDARY
Surgery Again
92.3; 81.3; 91.3; 6.4; 14.1; 7.6

Summary

The objective of this clinical investigation is to compare the safety and effectiveness of ProDisc-C to anterior cervical discectomy and fusion (ACDF) surgery in the treatment of symptomatic cervical disc disease (SCDD).

Eligibility Criteria

Inclusion Criteria

  • Symptomatic cervical disc disease (SCDD) in one vertebral level between C3-C7 defined as: Neck or arm (radicular) pain; and/or a functional/neurological deficit with at least one of the following conditions confirmed by imaging (CT, MRI or X-rays): Herniated nucleus pulposus; Spondylosis (defined by the presence of osteophytes); and/or Loss of disc height.
  • Age between 18 and 60 years.
  • Unresponsive to non-operative treatment for approximately six weeks or has the presence of progressive symptoms or signs of nerve root/spinal cord compression in the face of conservative treatment.
  • NDI score greater than or equal to 15/50 (30%).
  • Psychosocially, mentally and physically able to fully comply with the protocol including adhering to follow-up schedule and requirements and filling out forms.
  • Signed informed consent.

Exclusion Criteria

  • More than one vertebral level requiring treatment.
  • Marked cervical instability on resting lateral or flexion/extension radiographs: translation greater than 3mm and/or greater than 11 degrees of rotational difference to that of either adjacent level.
  • Has a fused level adjacent to the level to be treated.
  • Radiographic confirmation of severe facet joint disease or degeneration.
  • Known allergy to cobalt, chromium, molybdenum, titanium or polyethylene.
  • Clinically comprised vertebral bodies at the affected level(s) due to current or past trauma, e.g. by the radiographic appearance of fracture callus, malunion or nonunion.
  • Prior surgery at the level to be treated.
  • Severe spondylosis at the level to be treated as characterized by any of the following: Bridging osteophytes; A loss of disc height greater than 50%; or Absence of motion (<2°).
  • Neck or arm pain of unknown etiology.
  • Osteoporosis: A screening questionnaire for osteoporosis, SCORE (Simple Calculated Osteoporosis Risk Estimation), will be used to screen patients who require a DEXA (dual energy x-ray absoptiometry) bone mineral density measurement. If DEXA is required, exclusion will be defined as a DEXA bone density measured T score less than or equal to -2.5 (the World Health Organization definition of osteoporosis).
  • Paget's disease, osteomalacia or any other metabolic bone disease (excluding osteoporosis which is addressed above).
  • Severe diabetes mellitus requiring daily insulin management.
  • Pregnant or interested in becoming pregnant in the next three years.
  • Active infection - systemic or local.
  • Taking medications or any drug known to potentially interfere with bone/soft tissue healing (e.g., steroids).
  • Rheumatoid arthritis or other autoimmune disease.
  • Systemic disease including AIDS, HIV, hepatitis.
  • Active malignancy: A patient with a history of any invasive malignancy (except non-melanoma skin cancer), unless he/she has been treated with curative intent and there have been no clinical signs or symptoms of the malignancy for at least 5 years.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00291018). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search